Suppr超能文献

肿瘤坏死因子相关凋亡诱导配体:HIV免疫病理学中的TRAIL短轴

The TRAIL: TRAILshort Axis in HIV Immunopathology.

作者信息

Aboulnasr Fatma, Paranjape Geeta, Badley Andrew D

机构信息

Division of Infectious Diseases, Mayo Clinic, Rochester, MN 55905.

Continuing Studies, Duke University, Durham, NC, 22708.

出版信息

Crit Rev Immunol. 2018;38(6):491-503. doi: 10.1615/CritRevImmunol.2019029632.

Abstract

Accelerated loss of HIV-infected and uninfected CD4 T cells is a hallmark of HIV infection that leads to severe immunodeficiency, rendering the host susceptible to opportunistic infections and malignancies. Obstacles to eradicating HIV involve the virus's ability to remain in a quiescent state as latent viral reservoirs and manipulate host defenses to benefit viral survival and persistence of the infected reservoir. Several mechanisms cause CD4 T-cell depletion and recent studies demonstrate the role of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in this process. Expression of TRAIL and its receptors is upregulated in response to HIV infection. TRAIL interacts with its receptors to activate apoptotic pathways. We recently demonstrated the presence of TRAILshort, a novel splice variant of full-length TRAIL, in the serum of HIV-infected patients. A unique carboxy-terminus allows TRAILshort to bind to death receptors without inducing apoptosis and prevents TRAIL from binding to its receptors, thereby conferring resistance to TRAIL-mediated death. In this review, we describe how the TRAIL: TRAILshort receptor axis modulates apoptosis of different types of immune cells in the context of HIV infection. We also discuss how TRAIL and TRAILshort contribute to the activation of immune cells involved in host defense against HIV and mechanisms that HIV has evolved to manipulate TRAIL for its survival.

摘要

HIV 感染和未感染的 CD4 T 细胞加速损耗是 HIV 感染的一个标志,会导致严重免疫缺陷,使宿主易患机会性感染和恶性肿瘤。根除 HIV 的障碍包括病毒以潜伏病毒库形式处于静止状态的能力,以及操控宿主防御以利于病毒存活和感染库持续存在的能力。多种机制导致 CD4 T 细胞耗竭,最近的研究证明肿瘤坏死因子相关凋亡诱导配体(TRAIL)在这一过程中的作用。TRAIL 及其受体的表达在 HIV 感染后会上调。TRAIL 与其受体相互作用以激活凋亡途径。我们最近在 HIV 感染患者的血清中发现了 TRAILshort,这是全长 TRAIL 的一种新型剪接变体。独特的羧基末端使 TRAILshort 能够结合死亡受体而不诱导凋亡,并阻止 TRAIL 与其受体结合,从而赋予对 TRAIL 介导的死亡的抗性。在这篇综述中,我们描述了在 HIV 感染背景下,TRAIL:TRAILshort 受体轴如何调节不同类型免疫细胞的凋亡。我们还讨论了 TRAIL 和 TRAILshort 如何促进参与宿主抗 HIV 防御的免疫细胞的激活,以及 HIV 为了生存而进化出的操控 TRAIL 的机制。

相似文献

1
The TRAIL: TRAILshort Axis in HIV Immunopathology.
Crit Rev Immunol. 2018;38(6):491-503. doi: 10.1615/CritRevImmunol.2019029632.
3
TRAILshort Protects against CD4 T Cell Death during Acute HIV Infection.
J Immunol. 2019 Aug 1;203(3):718-724. doi: 10.4049/jimmunol.1900271. Epub 2019 Jun 12.
4
HIV elite control is associated with reduced TRAILshort expression.
AIDS. 2019 Sep 1;33(11):1757-1763. doi: 10.1097/QAD.0000000000002279.
5
Human Cancers Express TRAILshort, a Dominant Negative TRAIL Splice Variant, Which Impairs Immune Effector Cell Killing of Tumor Cells.
Clin Cancer Res. 2020 Nov 1;26(21):5759-5771. doi: 10.1158/1078-0432.CCR-20-0251. Epub 2020 Jul 15.
8
Plasmacytoid dendritic cells express TRAIL and induce CD4+ T-cell apoptosis in HIV-1 viremic patients.
Blood. 2009 Oct 29;114(18):3854-63. doi: 10.1182/blood-2009-04-217927. Epub 2009 Aug 18.
9
Isolation of a TRAIL antagonist from the serum of HIV-infected patients.
J Biol Chem. 2011 Oct 14;286(41):35742-35754. doi: 10.1074/jbc.M111.274639. Epub 2011 Aug 22.

本文引用的文献

1
Understanding the CD8 T-cell response in natural HIV control.
F1000Res. 2018 Jul 2;7. doi: 10.12688/f1000research.15029.1. eCollection 2018.
3
Interleukin-15-Stimulated Natural Killer Cells Clear HIV-1-Infected Cells following Latency Reversal .
J Virol. 2018 May 29;92(12). doi: 10.1128/JVI.00235-18. Print 2018 Jun 15.
4
The Murine Natural Cytotoxic Receptor NKp46/NCR1 Controls TRAIL Protein Expression in NK Cells and ILC1s.
Cell Rep. 2018 Mar 27;22(13):3385-3392. doi: 10.1016/j.celrep.2018.03.023.
5
Type I interferon and HIV: Subtle balance between antiviral activity, immunopathogenesis and the microbiome.
Cytokine Growth Factor Rev. 2018 Apr;40:19-31. doi: 10.1016/j.cytogfr.2018.03.003. Epub 2018 Mar 16.
6
Interferon-α Subtypes As an Adjunct Therapeutic Approach for Human Immunodeficiency Virus Functional Cure.
Front Immunol. 2018 Feb 22;9:299. doi: 10.3389/fimmu.2018.00299. eCollection 2018.
7
Tissue-Resident Cytolytic Innate Lymphocytes in Cancer.
J Immunol. 2018 Jan 15;200(2):408-414. doi: 10.4049/jimmunol.1701124.
8
Autoimmune lymphoproliferative syndrome: more than a FAScinating disease.
F1000Res. 2017 Nov 1;6:1928. doi: 10.12688/f1000research.11545.1. eCollection 2017.
9
Why do BCL-2 inhibitors work and where should we use them in the clinic?
Cell Death Differ. 2018 Jan;25(1):56-64. doi: 10.1038/cdd.2017.183. Epub 2017 Oct 27.
10
Natural killer cells in HIV-1 infection and therapy.
AIDS. 2017 Nov 13;31(17):2317-2330. doi: 10.1097/QAD.0000000000001645.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验